Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34474640 | 1.00 | CA1 (0.33) | CA1CA2PDE3ACA12HTR5A | |
| SCHEMBL17068939 | 0.82 | ADRA2A (0.33) | CA1CA2CA12HTR5AHTR2C | |
| SCHEMBL819543 | 0.82 | ADRA2A (0.33) | CA1CA2CA12HTR5AHTR2C | |
| SCHEMBL7676238 | 0.78 | FFAR4 (0.40) | CA1CA2PDE3ACA12HTR5A | |
| SCHEMBL7785600 | 0.78 | NOTUM (0.32) | CA1CA2PDE3AHTR5ANOTUM | |
| SCHEMBL21260400 | 0.75 | ALDH1A1 (0.34) | CA1CA2PDE3ACA12NOTUM | |
| SCHEMBL275981 | 0.74 | TUBB4A (0.30) | — | |
| SCHEMBL4007987 | 0.74 | PDE2A (0.35) | — | |
| SCHEMBL217518 | 0.73 | DRD2 (0.36) | CA1CA2CA12CA5ACA9 | |
| SCHEMBL1478133 | 0.73 | PNMT (0.35) | HTR2CAHRCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230159766-A1 | CONDUCTIVE POLYMER COMPOSITION, SUBSTRATE, AND METHOD FOR PRODUCING SUBSTRATE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20230159766-A1 | CONDUCTIVE POLYMER COMPOSITION, SUBSTRATE, AND METHOD FOR PRODUCING SUBSTRATE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-11208509-B2 | Polymer compound for conductive polymer and method for producing same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-12-28 | — | — | US | disclosed |
| CN-112105654-A | Curable resin mixture, curable resin composition, and cured product thereof | 日本化药株式会社 | 2020-12-18 | — | — | CN | disclosed |
| WO-2020252205-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200291145-A1 | POLYMER COMPOUND FOR CONDUCTIVE POLYMER AND METHOD FOR PRODUCING SAME | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-09-17 | — | — | US | disclosed |
| US-20200247926-A1 | POLYMERIZABLE MONOMER, POLYMER COMPOUND FOR CONDUCTIVE POLYMER, AND METHOD FOR PRODUCING THE POLYMER COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| WO-2020031935-A1 | CURABLE RESIN MIXTURE, CURABLE RESIN COMPOSITION, AND CURED PRODUCT | 日本化薬株式会社 | 2020-02-13 | — | — | WO | disclosed |
| WO-2013033620-A1 | COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20100286160-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | INTERVET INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286160-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | INTERVET INC. | 2010-11-11 | — | — | US | disclosed |
| WO-2009005671-A2 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| US-6087292-A | Metallocene catalysts comprising indenyl ligands substituted with electronegative groups | TANGOR GMBH (DE) | 2000-07-11 | — | — | US | disclosed |
| US-5763542-A | Process for the preparation of an olefin polymer using specific metallocenes | TARGOR GMBH (DE) | 1998-06-09 | — | — | US | disclosed |
| EP-0505972-B1 | Process for producing styrenic copolymer | IDEMITSU KOSAN CO (JP) | 1997-06-11 | — | — | EP | disclosed |
| US-5504232-A | Process for the preparation of an olefin polymer using specific metallocenes | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-04-02 | — | — | US | disclosed |
| EP-0505972-A2 | Process for producing styrenic copolymer | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286160-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | CNR1, CNR2, GPR119 | CA1 3472/4885CA2 3771/4885PDE3A 1180/4885 |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | GPER1, ESR1, ESRRA | CA1 3360/4885CA2 2920/4885PDE3A 1493/4885 |
| US-20200247926-A1 | POLYMERIZABLE MONOMER, POLYMER COMPOUND FOR CONDUCTIVE POLYMER, AND METHOD FOR PRODUCING THE POLYMER COMPOUND | HCN4, HCN2, HCN3 | CA1 571/4885CA2 314/4885PDE3A 4521/4885 |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | CA1 1200/4885CA2 1299/4885PDE3A 36/4885 |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | CA1 1403/4885CA2 3747/4885PDE3A 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.